Cubist Pharmaceuticals Inc.
) to beat expectations when it releases its fourth-quarter 2012
results on Jan 23, 2013.
Why a Likely Positive Surprise?
Our proven model shows that Cubist Pharma is likely to beat
earnings because it has the right combination of two key
(Expected Surprise Prediction): This is because the Most Accurate
estimate stands at 53 cents while the Zacks Consensus is lower at
48 cents. This results in a difference of +10.42%.
Zacks Rank #3 (Hold)
: Note that stocks with Zacks Rank of #1, #2 and #3 have a
significantly higher chance of beating earnings. The sell rated
stocks (#4 and #5) should never be considered while going into an
The combination of Cubist Pharma's Zacks Rank # 3 (Hold) and
+10.42% ESP causes us to expect a positive earnings beat on Jan
What is Driving the Better Than Expected
Cubist Pharma is expected to deliver a positive earnings
surprise in the final quarter of 2012 riding on strong sales of
its antibiotic once-daily, intravenous injection Cubicin. The
Zacks Consensus Estimate for the fourth quarter has moved up by 3
cents to 48 cents per share over the last 30 days due to the
obvious positive sentiment.
This biopharmaceutical company has delivered positive earnings
surprises in 3 of the last 4 quarters with an average beat of
4.09%. The impressive performance over the last few quarters is
attributable to strong revenues, thanks to impressive Cubicin
Other Stocks to Consider
Here are some other pharma companies you may want to consider
on the basis of our model, which shows that they have the right
combination of elements to post an earnings beat this
) has Earnings ESP of +1.35% and carries a Zacks Rank #2
) has Earnings ESP of +4.69% and carries a Zacks Rank #2
) has Earnings ESP of +5.80% and carries a Zacks Rank #3
ASTRAZENECA PLC (AZN): Free Stock Analysis
CUBIST PHARM (CBST): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.